| 0.4957 0.129 (34.99%) | 11-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.65  |
1-year : | 0.83 |
| Resists | First : | 0.56 |
Second : | 0.71 |
| Pivot price | 0.4 |
|||
| Supports | First : | 0.31 | Second : | 0.26 |
| MAs | MA(5) : | 0.39 |
MA(20) : | 0.42 |
| MA(100) : | 1.18 |
MA(250) : | 1.85 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 49.3 |
D(3) : | 39.7 |
| RSI | RSI(14): 44.4 |
|||
| 52-week | High : | 3.65 | Low : | 0.31 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NMRA ] has closed below upper band by 11.1%. Bollinger Bands are 63.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.41 - 0.41 | 0.41 - 0.41 |
| Low: | 0.35 - 0.35 | 0.35 - 0.35 |
| Close: | 0.36 - 0.37 | 0.37 - 0.37 |
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Sat, 29 Aug 2026
Insiders Sold Neumora Therapeutics Prematurely At US$2.29 With Stock Trading Higher - Simply Wall St
Fri, 21 Aug 2026
Neumora Therapeutics COO Aurora disposes of $269,966 in stock - Investing.com
Wed, 19 Aug 2026
Neumora Therapeutics COO Daljit Aurora sells $431,674 in stock - Investing.com
Thu, 25 Jun 2026
NMRA Forecast — Price Target — Prediction for 2027 - TradingView
Tue, 16 Jun 2026
Should I buy Neumora Therapeutics, Inc. (NMRA) - Zacks Investment Research
Mon, 15 Jun 2026
Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 188 (M) |
| Shares Float | 116 (M) |
| Held by Insiders | 23 (%) |
| Held by Institutions | 60.1 (%) |
| Shares Short | 6,690 (K) |
| Shares Short P.Month | 8,030 (K) |
| EPS | -1.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.23 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -73.9 % |
| Return on Equity (ttm) | -187.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -181 (M) |
| Levered Free Cash Flow | -99 (M) |
| PE Ratio | -0.39 |
| PEG Ratio | 0 |
| Price to Book value | 1.97 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.5 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|